Working… Menu

Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03073525
Recruitment Status : Active, not recruiting
First Posted : March 8, 2017
Last Update Posted : March 15, 2021
Information provided by (Responsible Party):
Gradalis, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : January 1, 2021
Estimated Study Completion Date : September 30, 2022
Publications of Results:
Rodney Paul Rocconi, Erin E. Stevens, Justin N. Bottsford-Miller, Sharad A. Ghamande, Phylicia Aaron, Gladice Wallraven, Ernest Bognar, Meghan Manley, Staci Horvath, Luisa Manning, John J. Nemunaitis, Thomas J Herzog, Bradley J. Monk, Robert L. Coleman, and Vigil Team (2020), A phase I combination study of vigil and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients. DOI: 10.1200/JCO.2020.38.15_suppl.3002 Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3002-3002.

Other Publications:
Senzer N, Barve M, Nemunaitis J, Kuhn J, Melnyk A, et al. (2013) Long Term Follow Up: Phase I Trial of "Bi-Shrnafurin/GMCSF DNA/Autologous Tumor Cell" Immunotherapy (FANG™) in Advanced Cancer. J Vaccines Vaccin 4:209. doi:10.4172/2157-7560.1000209